Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Buys 2,000 Shares

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel acquired 2,000 shares of the stock in a transaction on Thursday, January 2nd. The stock was bought at an average price of $11.97 per share, with a total value of $23,940.00. Following the transaction, the chief executive officer now directly owns 5,543,702 shares of the company’s stock, valued at approximately $66,358,112.94. The trade was a 0.04 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Snehal Patel also recently made the following trade(s):

• On Monday, December 30th, Snehal Patel bought 3,200 shares of Greenwich LifeSciences stock. The stock was purchased at an average cost of $11.12 per share, for a total transaction of $35,584.00.

Greenwich LifeSciences Stock Up 5.3 %

Shares of GLSI opened at $13.81 on Wednesday. The firm has a fifty day simple moving average of $13.18 and a two-hundred day simple moving average of $14.14. Greenwich LifeSciences, Inc. has a twelve month low of $8.00 and a twelve month high of $21.44. The stock has a market capitalization of $181.53 million, a P/E ratio of -17.26 and a beta of 1.66.

Institutional Trading of Greenwich LifeSciences

Several large investors have recently modified their holdings of the business. State Street Corp raised its position in Greenwich LifeSciences by 4.4% during the 3rd quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after purchasing an additional 3,005 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Greenwich LifeSciences by 4.6% during the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock valued at $1,919,000 after buying an additional 5,861 shares during the period. Barclays PLC raised its holdings in shares of Greenwich LifeSciences by 323.3% during the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after acquiring an additional 6,538 shares in the last quarter. Rhumbline Advisers purchased a new stake in Greenwich LifeSciences in the second quarter worth $117,000. Finally, Bank of New York Mellon Corp bought a new stake in Greenwich LifeSciences in the second quarter valued at $264,000. 4.16% of the stock is owned by institutional investors.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.